Long-Term Investments (Details) - Schedule of long-term investment - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Non-marketable Cost Method Investments, net
Sub total	$ 904,254	$ 932,755
Equity Method Investments, net
Total	904,254	932,755
Braingenesis Biotechnology Co., Ltd. [Member]
Non-marketable Cost Method Investments, net
Sub total	7,698	7,941
Genepharm Biotech Corporation [Member]
Non-marketable Cost Method Investments, net
Sub total	23,503	24,244
BioHopeKing Corporation [Member]
Non-marketable Cost Method Investments, net
Sub total	873,053	900,570
BioFirst Corporation [Member]
Equity Method Investments, net
Total
Rgene Corporation [Member]
Equity Method Investments, net
Total

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

Name:	us-gaap_EquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant